DLBCL

ASCO 2022 Lymphoma In-Depth Bookmark

Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.

.

First Approval of Second-Line Therapy for DLBCL Bookmark

Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

.